In message <[log in to unmask]>,
[log in to unmask] writes
>>
>Bollocks. The published *and* unpublished data show *NO* difference
>in clinically relevant or quality of life indicators at 13 or 26
>weeks. (I await the next study in Dementia soon with "interest"). Ok
>so things like fancy clinical scoring systems show statistically
>significant benefits over placebo, the evidence clearly shows that
>this makes *NO* difference to the patient and/or carers.
>
The problem is that it is impossible to generalise the findings of the
available trials to individuals. I am beginning to suspect that this is
a drug which may provide useful benefits to a small number of patients,
but not to the majority. It's not the same as treating hypertension or
hypercholesterolaemia in which all we do is modify risk (and can
calculate exactly how much the risk is changed).
>> I've prescribed it once , Its not very exciting.
>>
>If it's going to be prescribed it should be by a consultant. The
>licence is *only* for Alzeihmer's, other organic dementias or pseudo
>dementias should be excluded first
I'm not so sure. Maybe we should learn how to do "N of 1" trials
Toby
--
Toby Lipman 7, Collingwood Terrace, Jesmond, Newcastle upon Tyne. Tel
0191-2811060 (home), 0191-2437000 (surgery)
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
|